📊 NBIX Key Takeaways
Is Neurocrine Biosciences Inc. (NBIX) a Good Investment?
Neurocrine demonstrates exceptional fundamental strength with revenue growth of 21.4% YoY coupled with outstanding net income growth of 40.2% YoY, indicating significant operating leverage and margin expansion. The company maintains a fortress-like balance sheet with zero meaningful debt, strong liquidity (2.93x current ratio), and robust free cash flow generation of $136.7M, providing financial flexibility and downside protection.
Strong 21%+ revenue growth, double‑digit operating and net margins, and a debt‑free, highly liquid balance sheet underscore sound fundamentals. Despite flat net income YoY, cash generation is robust (26% FCF margin), supporting continued R&D and commercialization without balance‑sheet strain.
Neurocrine Biosciences Inc. Key Strengths (NBIX)
- Outstanding growth profile with 21.4% revenue growth and 40.2% net income growth demonstrating strong operating leverage and margin expansion
- Fortress balance sheet with zero debt (0.00x debt/equity), exceptional liquidity (2.93x current ratio), and robust free cash flow of $136.7M
- Exceptional profitability with 24.3% net margin and 23.7% operating margin, well above industry average for biotech
- Rapid topline growth with solid operating margin (21.6%)
- Debt-free, excellent liquidity (3.39x current) and massive interest coverage
- Strong cash generation ($783M OCF; 26% FCF margin)
NBIX Stock Risks: Neurocrine Biosciences Inc. Investment Risks
- Biotech sector inherent risks including regulatory approval uncertainties, clinical trial failures, and patent cliff exposure
- Moderate capital efficiency with ROE of 5.8% and ROA of 4.0% suggesting potential capital deployment challenges
- Revenue concentration risk and dependency on successful commercialization of limited product portfolio
- Flat net income YoY suggests rising costs or one‑offs
- Biopharma regulatory/reimbursement and product concentration risk
- Gross margin not reported, reducing cost-structure visibility
Key Metrics to Watch
- Revenue growth rate sustainability and product pipeline progress
- Operating margin maintenance and ability to sustain 23%+ margins at scale
- Free cash flow generation trends and capital allocation strategy for cash deployment
- Operating margin trend and R&D/SG&A as % of revenue
- Free cash flow margin and OCF growth vs. revenue
Neurocrine Biosciences Inc. (NBIX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.93x current ratio provides a solid financial cushion.
NBIX Profit Margin, ROE & Profitability Analysis
NBIX vs Healthcare Sector: How Neurocrine Biosciences Inc. Compares
How Neurocrine Biosciences Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Neurocrine Biosciences Inc. Stock Overvalued? NBIX Valuation Analysis 2026
Based on fundamental analysis, Neurocrine Biosciences Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Neurocrine Biosciences Inc. Balance Sheet: NBIX Debt, Cash & Liquidity
NBIX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Neurocrine Biosciences Inc.'s revenue has grown significantly by 152% over the 5-year period, indicating strong business expansion. The most recent EPS of $2.47 reflects profitable operations.
NBIX Revenue Growth, EPS Growth & YoY Performance
NBIX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $572.6M | $7.9M | $0.08 |
| Q3 2025 | $622.1M | $129.8M | $1.24 |
| Q2 2025 | $590.2M | $65.0M | $0.63 |
| Q1 2025 | $515.3M | $7.9M | $0.08 |
| Q3 2024 | $498.8M | $83.1M | $0.82 |
| Q2 2024 | $452.7M | $18.9M | $0.19 |
| Q1 2024 | $420.4M | $43.4M | $0.42 |
| Q3 2023 | $387.9M | $65.5M | $0.67 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Neurocrine Biosciences Inc. Dividends, Buybacks & Capital Allocation
NBIX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Neurocrine Biosciences Inc. (CIK: 0000914475)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 21, 2026 | 4 | xslF345X06/wk-form4_1779405893.xml | View → |
| May 21, 2026 | 4 | xslF345X06/wk-form4_1779405862.xml | View → |
| May 21, 2026 | 4 | xslF345X06/wk-form4_1779405838.xml | View → |
| May 21, 2026 | 4 | xslF345X06/wk-form4_1779405806.xml | View → |
| May 21, 2026 | 4 | xslF345X06/wk-form4_1779405768.xml | View → |
❓ Frequently Asked Questions about NBIX
What is the AI rating for NBIX?
Neurocrine Biosciences Inc. (NBIX) has a Combined AI Grade of A from Claude (A+) and ChatGPT (A) with 81% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NBIX's key strengths?
Claude: Outstanding growth profile with 21.4% revenue growth and 40.2% net income growth demonstrating strong operating leverage and margin expansion. Fortress balance sheet with zero debt (0.00x debt/equity), exceptional liquidity (2.93x current ratio), and robust free cash flow of $136.7M. ChatGPT: Rapid topline growth with solid operating margin (21.6%). Debt-free, excellent liquidity (3.39x current) and massive interest coverage.
What are the risks of investing in NBIX?
Claude: Biotech sector inherent risks including regulatory approval uncertainties, clinical trial failures, and patent cliff exposure. Moderate capital efficiency with ROE of 5.8% and ROA of 4.0% suggesting potential capital deployment challenges. ChatGPT: Flat net income YoY suggests rising costs or one‑offs. Biopharma regulatory/reimbursement and product concentration risk.
What is NBIX's revenue and growth?
Neurocrine Biosciences Inc. reported revenue of $814.5M.
Does NBIX pay dividends?
Neurocrine Biosciences Inc. does not currently pay dividends.
Where can I find NBIX SEC filings?
Official SEC filings for Neurocrine Biosciences Inc. (CIK: 0000914475) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NBIX's EPS?
Neurocrine Biosciences Inc. has a diluted EPS of $1.91.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is NBIX's fundamental grade?
Based on our AI fundamental analysis in May 2026, Neurocrine Biosciences Inc. has a A grade with 81% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is NBIX stock overvalued or undervalued?
Valuation metrics for NBIX: ROE of 5.8% (sector avg: 15%), net margin of 24.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is NBIX's AI grade for 2026?
Our dual AI analysis gives Neurocrine Biosciences Inc. a combined A grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is NBIX's free cash flow?
Neurocrine Biosciences Inc.'s operating cash flow is $145.8M, with capital expenditures of $9.1M. FCF margin is 16.8%.
How does NBIX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 24.3% (avg: 12%), ROE 5.8% (avg: 15%), current ratio 2.93 (avg: 2).